/PRNewswire/ AbbVie (NYSE: ABBV) today announced that data from its robust migraine portfolio will be presented at the 16th European Headache Federation.
/PRNewswire/ AbbVie (NYSE: ABBV) today announced that new data from its migraine portfolio will be presented at the Migraine Trust International Symposium.
AbbVie today announced that new data from its migraine portfolio will be presented at the Migraine Trust International Symposium (MTIS) 2022, taking place in London from September 8-11.
Share:
ResearchAndMarkets.com s offering.
Global Migraine Epidemiology and Patient Flow Analysis - 2021, provides Migraine epidemiology, demographics, and patient flow. The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.
The research provides population data to characterize Migraine patients, history of the disease at the population level (Migraine prevalence, Migraine incidence) and at the clinical level (from diagnosis to treated patients). It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.
Research scope:
Countries: US, Germany, France, Italy, Spain, UK, Japan, G7 Countries
Demographics: Migraine patients by age group, gender
ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the migraine, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Migraine epidemiology segmented as the Total Prevalent Cases of Migraine, Severity-specific cases of Migraine, Gender-specific cases of Migraine, Diagnosed Cases of Episodic and Chronic Migraine. The report includes the Incident scenario of Migraine symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.